Global Position Statement on the use of testosterone in the treatment of women
The first international consensus statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), has been published this Monday in four leading international medical journals.
For the first time, the Global Position Statement provides consensus from leading experts in the field about the known benefits and potential risks of testosterone therapy for premenopausal and postmenopausal women.
With the statement, the international panel not only provides advice to both health care professionals and women in or near menopausal age (35-65). It also calls for action the industry, researchers and funding organisations to recognize the need for further research into testosterone therapy for menopausal women and for development and licensing of products indicated specifically for women.
The Global Position Statement has been developed by nine leading medical organisations from across the world including The International Menopause Society; The International Society for Sexual Medicine; The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia; The American College of Obstetricians and Gynecologists, The North American Menopause Society, The European Menopause and Andropause Society; The International Society for the Study of Women’s Sexual Health, The Royal College of Obstetricians and Gynaecologists and The Endocrine Society, and endorsed by several additional Societies.
To find out more, read the full Global Position Statement here >>
Check what the leading medical media has published on the topic here.
Learn more about the International Menopause Society on their Official website.